<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625466</url>
  </required_header>
  <id_info>
    <org_study_id>VX16-809-121</org_study_id>
    <secondary_id>2017-003761-99</secondary_id>
    <nct_id>NCT03625466</nct_id>
  </id_info>
  <brief_title>A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del</brief_title>
  <official_title>An Exploratory Phase 2, 2-part, Randomized, Double-blind, Placebo-controlled Study With a Long-term, Open-label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression
      in subjects aged 2 through 5 years with cystic fibrosis (CF), homozygous for F508del (F/F)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded in Part one, and Open label in Part 2</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in magnetic resonance imaging (MRI) global chest score</measure>
    <time_frame>from baseline at Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in lung clearance index (LCI)2.5</measure>
    <time_frame>from baseline through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in weight-for-age z-score</measure>
    <time_frame>from baseline at Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in stature-for-age z-score</measure>
    <time_frame>from baseline at Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body mass index (BMI)-for-age z-score</measure>
    <time_frame>from baseline at Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part 1: Double Blind Period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive LUM/IVA as FDC granules dependent upon weight or matched placebo at Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Open Label Period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive LUM/IVA as FDC tablets or granules dependent upon weight at Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUM</intervention_name>
    <description>Fixed-dose combination (FDC) granule (LUM/IVA)</description>
    <arm_group_label>Part 1: Double Blind Period</arm_group_label>
    <arm_group_label>Part 2: Open Label Period</arm_group_label>
    <other_name>Lumacaftor</other_name>
    <other_name>VX-809</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>FDC tablet or granule (LUM/IVA)</description>
    <arm_group_label>Part 1: Double Blind Period</arm_group_label>
    <arm_group_label>Part 2: Open Label Period</arm_group_label>
    <other_name>Ivacaftor</other_name>
    <other_name>VX-770</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebos</intervention_name>
    <description>Placebo will be used as a comparator.</description>
    <arm_group_label>Part 1: Double Blind Period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects with confirmed diagnosis of CF.

          -  Homozygous for F508del (F/F).

          -  Subjects who weigh ≥8 kg without shoes and wearing light clothing at the Screening
             Visit.

        Key Exclusion Criteria:

          -  Any clinically significant laboratory abnormalities at the Screening Visit that would
             interfere with the study assessments or pose an undue risk for the subject.

          -  Solid organ or hematological transplantation.

          -  History of any illness or comorbidity reviewed at the Screening Visit that, in the
             opinion of the investigator, might confound the results of the study.

        Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charite Paediatric Pulmonology Department</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Leibig-Universitat Zentrum fur Kinderheilkunde und Jugendmedizin</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg Cystic Fibrosis Center</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein, Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Lubeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

